GlassScriptPhysician profile
Duy Tuong Vy
NPI 1104952993
$3,809.03
in general payments reported to CMS, 2019-2025
14 companies · $686 in 2025
The $686 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $66.02 · 2021: $653 · 2022: $662 · 2023: $424 · 2024: $634 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,261.98 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Cvi Contact Lens |
| Bausch & Lomb Americas INC. | $652.69 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $556.63 | 2022-2025 | Dailies Total1, Precision7, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $421.53 | 2019-2021 | |
| Topcon Healthcare, INC. | $191.67 | 2021 | |
| Optovue, INC. | $160.32 | 2019-2021 | |
| Optos, INC. | $153.95 | 2021-2022 | |
| Glaukos Corporation | $142.00 | 2025 | Photrexa Viscous and Photrexa |
| Lombart Brothers, INC. | $138.32 | 2024 | Opd-III |
| Maculogix, INC. | $43.01 | 2019 | |
| Visionix USA, INC | $40.00 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Abb Con-Cise Optical Group LLC | $10.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duy Vy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.